Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a price target of $26.
August 23, 2024 | 5:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals and maintained a price target of $26, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $26 price target by a reputable analyst suggests a positive outlook for Phathom Pharmaceuticals. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100